Eli Lilly & Co. (LLY) Misses Q1 EPS by 12c; updates guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/27/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Eli Lilly (LLY) sell-off 'overdone' on CVS move on Wegovy - Leerink
May 2, 2025 9:33 AM EDTLeerink Partners analyst David Risinger reiterated an Outperform rating and $944.00 price target on Eli Lilly (NYSE: LLY), saying yesterday's 12% pullback creates a buying opportunity.
The analyst commented, "Despite LLY downplaying CVS Caremarks action favoring Wegovy over Zepbound, LLY shares declined 11.7% yesterday.... More
